Invention Application
- Patent Title: ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
- Patent Title (中): 抗IgSF4抗体及其应用
-
Application No.: PCT/JP2006303195Application Date: 2006-02-22
-
Publication No.: WO2006090750A8Publication Date: 2008-01-10
- Inventor: KUROSAWA YOSHIKAZU , AKAHORI YASUSHI , SUGIOKA ATSUSHI , HAYASHI NOBUHIRO , TAKASAKI AKIHIKO , SUZUKI KAZUHIRO , MORITA MIWA , KUROSAWA GENE , IBA YOSHITAKA , SUMITOMO MARIKO , TSUTSUMI SUSUMU , OGAWA KEIKO , MATSUDA KAZUKI , MURAMATSU CHIHO , TAKAHASHI NOBUHIRO , FUJIYAMA SARI , AZUMA MASACHIKA , UKAI YOSHINORI , MORISHITA KAZUHIRO
- Applicant: INST ANTIBODIES CO LTD , KUROSAWA YOSHIKAZU , AKAHORI YASUSHI , SUGIOKA ATSUSHI , HAYASHI NOBUHIRO , TAKASAKI AKIHIKO , SUZUKI KAZUHIRO , MORITA MIWA , KUROSAWA GENE , IBA YOSHITAKA , SUMITOMO MARIKO , TSUTSUMI SUSUMU , OGAWA KEIKO , MATSUDA KAZUKI , MURAMATSU CHIHO , TAKAHASHI NOBUHIRO , FUJIYAMA SARI , AZUMA MASACHIKA , UKAI YOSHINORI , MORISHITA KAZUHIRO
- Assignee: INST ANTIBODIES CO LTD,KUROSAWA YOSHIKAZU,AKAHORI YASUSHI,SUGIOKA ATSUSHI,HAYASHI NOBUHIRO,TAKASAKI AKIHIKO,SUZUKI KAZUHIRO,MORITA MIWA,KUROSAWA GENE,IBA YOSHITAKA,SUMITOMO MARIKO,TSUTSUMI SUSUMU,OGAWA KEIKO,MATSUDA KAZUKI,MURAMATSU CHIHO,TAKAHASHI NOBUHIRO,FUJIYAMA SARI,AZUMA MASACHIKA,UKAI YOSHINORI,MORISHITA KAZUHIRO
- Current Assignee: INST ANTIBODIES CO LTD,KUROSAWA YOSHIKAZU,AKAHORI YASUSHI,SUGIOKA ATSUSHI,HAYASHI NOBUHIRO,TAKASAKI AKIHIKO,SUZUKI KAZUHIRO,MORITA MIWA,KUROSAWA GENE,IBA YOSHITAKA,SUMITOMO MARIKO,TSUTSUMI SUSUMU,OGAWA KEIKO,MATSUDA KAZUKI,MURAMATSU CHIHO,TAKAHASHI NOBUHIRO,FUJIYAMA SARI,AZUMA MASACHIKA,UKAI YOSHINORI,MORISHITA KAZUHIRO
- Priority: JP2005054624 2005-02-28
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00 ; A61P35/00 ; C12N1/15 ; C12N1/19 ; C12N1/21 ; C12N5/10 ; C12N15/09 ; C12Q1/02 ; G01N33/15 ; G01N33/50
Abstract:
It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, an ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.
Information query
